Bob Tingkan Li

Dr. Bob Tingkan Li is an Associate Professor in the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK), specializing in Thoracic Oncology within the Solid Tumor Oncology Division. His research focuses on advancing precision medicine approaches for lung cancer through molecular profiling and targeted therapies, with particular expertise in KRAS and HER2 mutations.

Dr. Li's research interests center on thoracic oncology, with specific emphasis on circulating tumor DNA applications, molecular profiling of lung cancers, and targeted therapies for KRAS and HER2 mutations. His work bridges clinical practice with genomic analysis, developing biomarkers that predict treatment response and resistance mechanisms. He has made significant contributions to understanding the molecular determinants of sotorasib efficacy in KRAS G12C-mutated lung cancer and the therapeutic implications of diverse ERBB2/ERBB3 alterations across solid tumors.

Analysis of Dr. Li's recent publications reveals a strong focus on translational research with immediate clinical applications. His work spans from fundamental molecular discovery (identifying determinants of treatment efficacy) to practical implementation (remote monitoring technologies, real-world data integration). A significant portion of his research addresses the clinical utility of circulating tumor DNA for non-invasive molecular profiling, minimal residual disease detection, and treatment response monitoring across various cancer types.

• Weinberg Fellow at MSK
• GSK Faculty Member

Dr. Li leads multiple collaborative research initiatives focused on precision oncology, working closely with the Solid Tumor Oncology Division and Thoracic Oncology service at MSK. His laboratory and research team specialize in integrating genomic data with clinical outcomes to develop predictive biomarkers and optimize targeted therapy approaches. Current research directions include refining ctDNA-based monitoring strategies, understanding mechanisms of resistance to targeted therapies, and developing novel treatment paradigms for molecularly defined subsets of lung cancer.